News articles about Laboratory Corp. of America (NYSE:LH) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Laboratory Corp. of America earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.3034713258049 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Laboratory Corp. of America stock traded down $1.42 during midday trading on Monday, reaching $160.33. The company’s stock had a trading volume of 1,287,558 shares, compared to its average volume of 674,980. Laboratory Corp. of America has a fifty-two week low of $134.19 and a fifty-two week high of $181.71. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.20 and a current ratio of 1.31. The company has a market cap of $16,482.33, a P/E ratio of 16.70, a price-to-earnings-growth ratio of 1.36 and a beta of 0.94.
Laboratory Corp. of America (NYSE:LH) last released its earnings results on Tuesday, February 6th. The medical research company reported $2.45 EPS for the quarter, beating analysts’ consensus estimates of $2.38 by $0.07. Laboratory Corp. of America had a return on equity of 16.30% and a net margin of 12.15%. The company had revenue of $2.70 billion during the quarter, compared to the consensus estimate of $2.70 billion. During the same quarter last year, the company earned $2.15 earnings per share. Laboratory Corp. of America’s quarterly revenue was up 13.2% compared to the same quarter last year. sell-side analysts predict that Laboratory Corp. of America will post 11.54 EPS for the current year.
In other news, Director Adam H. Schechter sold 1,263 shares of Laboratory Corp. of America stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $169.29, for a total transaction of $213,813.27. Following the completion of the transaction, the director now owns 7,297 shares of the company’s stock, valued at approximately $1,235,309.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David P. King sold 49,967 shares of Laboratory Corp. of America stock in a transaction on Friday, March 23rd. The stock was sold at an average price of $164.75, for a total value of $8,232,063.25. Following the transaction, the chief executive officer now directly owns 231,202 shares of the company’s stock, valued at approximately $38,090,529.50. The disclosure for this sale can be found here. In the last three months, insiders sold 59,630 shares of company stock valued at $9,851,701. 0.90% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.wkrb13.com/2018/04/03/laboratory-corp-of-america-lh-getting-somewhat-positive-press-coverage-study-shows.html.
Laboratory Corp. of America Company Profile
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.